Taysha Gene Therapies to Participate in Upcoming Investor Healthcare Conference and CEO Forum
June 15 2021 - 7:00AM
Business Wire
LifeSci Genetics Medicine Conference on June
22, 2021 at 10:00 am ET
LSX Biotech Growth CEO Forum on June 22, 2021
at 1:10 pm ET
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric,
pivotal-stage gene therapy company focused on developing and
commercializing AAV-based gene therapies for the treatment of
monogenic diseases of the central nervous system (CNS) in both rare
and large patient populations, today announced its participation in
virtual fireside chats at the LifeSci Genetics Medicine Conference
and LSX Biotech Growth CEO Forum.
Conferences Details:
Event:
LifeSci Genetics Medicine Conference
Date:
Tuesday, June 22, 2021
Time:
10:00 am ET
Format:
Fireside chat
Participants:
RA Session II, President, Founder and
CEO
Dr. Suyash Prasad, Chief Medical Officer
and Head of R&D
Kamran Alam, Chief Financial Officer
Event:
LSX Biotech Growth CEO Forum
Topic:
“Too Much of a Good Thing Can be
Wonderful: Optimizing Value From Broad Discovery Platforms Through
Strategy and Strategic Partnering”
Date:
Tuesday, June 22, 2021
Time:
1:10 pm ET
Format:
Fireside chat
Participants:
RA Session II, President, Founder and
CEO
Webcasts for these conferences will be available in the “Events
& Media” section of the Taysha corporate website at
https://ir.tayshagtx.com/news-events/events-presentations. Archived
versions of the webcasts will be available on the website for 60
days.
About Taysha Gene Therapies
Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to
eradicate monogenic CNS disease. With a singular focus on
developing curative medicines, we aim to rapidly translate our
treatments from bench to bedside. We have combined our team’s
proven experience in gene therapy drug development and
commercialization with the world-class UT Southwestern Gene Therapy
Program to build an extensive, AAV gene therapy pipeline focused on
both rare and large-market indications. Together, we leverage our
fully integrated platform—an engine for potential new cures—with a
goal of dramatically improving patients’ lives. More information is
available at www.tayshagtx.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210615005336/en/
Company Contact: Kimberly Lee, D.O. SVP, Corporate
Communications and Investor Relations Taysha Gene Therapies
klee@tayshagtx.com
Media Contact: Carolyn Hawley Canale Communications
carolyn.hawley@canalecomm.com
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Taysha Gene Therapies (NASDAQ:TSHA)
Historical Stock Chart
From Apr 2023 to Apr 2024